Department of Specialized, Experimental & Diagnostic Medicine, S.Orsola-Malpighi University Hospital, Alma Mater Studiorum University of Bologna, Bologna 40126, Italy.
Drug Development Department, Gustave Roussy Cancer Campus, 114 Rue Edouard Vaillant, Villejuif 94800, France.
Future Oncol. 2020 Aug;16(23):1683-1690. doi: 10.2217/fon-2020-0183. Epub 2020 Jun 1.
Immune checkpoint inhibition completely changed our approach of cancer therapeutics and led to interesting response rate in a wide spectrum of tumors. However, only a portion of patients benefits from immune checkpoint blockers. To improve response rates, monoclonal antibodies targeting costimulatory receptors called PD-1 or CTLA-4 are combined together or with different therapies such as chemotherapy or antiangiogenic drugs. Some of these combinations are already approved and used in daily practice, but the safety and efficacy in particular populations such as older patients, Eastern Cooperative Organization performance status 2 or patients taking corticosteroids or antibiotics remain unclear. This special report focuses on the data available for these populations with a focus on non-small-cell lung cancer.
免疫检查点抑制完全改变了我们的癌症治疗方法，并在广泛的肿瘤谱中产生了有趣的反应率。然而，只有一部分患者从免疫检查点阻滞剂中获益。为了提高反应率，靶向称为 PD-1 或 CTLA-4 的共刺激受体的单克隆抗体被联合使用，或与不同的疗法（如化疗或抗血管生成药物）联合使用。其中一些组合已经获得批准并在日常实践中使用，但在特定人群（如老年患者、东部合作组织表现状态 2 或服用皮质类固醇或抗生素的患者）中的安全性和疗效仍不清楚。本特别报告重点介绍了这些人群的可用数据，重点是非小细胞肺癌。
